Mark J. Ratain

37.9k total citations · 10 hit papers
532 papers, 23.0k citations indexed

About

Mark J. Ratain is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark J. Ratain has authored 532 papers receiving a total of 23.0k indexed citations (citations by other indexed papers that have themselves been cited), including 257 papers in Oncology, 205 papers in Molecular Biology and 95 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark J. Ratain's work include Cancer therapeutics and mechanisms (108 papers), Cancer Treatment and Pharmacology (93 papers) and Pharmacogenetics and Drug Metabolism (84 papers). Mark J. Ratain is often cited by papers focused on Cancer therapeutics and mechanisms (108 papers), Cancer Treatment and Pharmacology (93 papers) and Pharmacogenetics and Drug Metabolism (84 papers). Mark J. Ratain collaborates with scholars based in United States, Japan and China. Mark J. Ratain's co-authors include Federico Innocenti, Jacqueline Ramı́rez, Richard L. Schilsky, Lalitha Iyer, Walter M. Stadler, Linda Janisch, Lillian L. Siu, Philippe L. Bédard, Aaron R. Hansen and Soma Das and has published in prestigious journals such as Nature, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Mark J. Ratain

520 papers receiving 22.5k citations

Hit Papers

Tumour heterogeneity in t... 1998 2026 2007 2016 2013 2006 2004 2016 1998 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tumour heterogeneity in the clinic
    2013 897 citations Mark J. Ratain et al. profile →
  2. Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma
    2006 794 citations Mark J. Ratain, Tim Eisen et al. Journal of Clinical Oncology profile →
  3. Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan
    2004 695 citations Federico Innocenti, Samir D. Undevia et al. Journal of Clinical Oncology profile →
  4. Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)
    2016 585 citations Mark J. Ratain, Christopher K. Daugherty et al. profile →
  5. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
    1998 541 citations Mark J. Ratain et al. profile →
  6. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
    2002 521 citations Soma Das, Linda Janisch et al. The Pharmacogenomics Journal profile →
  7. Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
    2011 445 citations Ezra E.W. Cohen, Linda Janisch et al. Journal of Clinical Oncology profile →
  8. The development of a financial toxicity patient‐reported outcome in cancer: The COST measure
    2014 445 citations Mark J. Ratain, Christopher K. Daugherty et al. profile →
  9. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors
    2018 434 citations Theodore Karrison, Yuanyuan Zha et al. Journal of Clinical Oncology profile →
  10. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy
    2018 237 citations Howard L. McLeod, Mark J. Ratain et al. Clinical Pharmacology & Therapeutics profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Mark J. Ratain 10.2k 9.1k 4.3k 3.1k 2.8k 532 23.0k
Howard L. McLeod 10.1k 1.0× 9.6k 1.0× 2.6k 0.6× 2.9k 0.9× 6.6k 2.3× 481 26.6k
Jan H.M. Schellens 22.6k 2.2× 16.1k 1.8× 6.4k 1.5× 3.7k 1.2× 3.6k 1.3× 882 41.1k
Richard L. Schilsky 13.8k 1.3× 4.8k 0.5× 6.0k 1.4× 5.3k 1.7× 565 0.2× 382 23.2k
Tito Fojo 13.2k 1.3× 11.7k 1.3× 2.1k 0.5× 4.7k 1.5× 699 0.2× 265 24.3k
Henk‐Jan Guchelaar 4.6k 0.4× 4.1k 0.4× 1.9k 0.4× 1.7k 0.6× 3.7k 1.3× 452 15.7k
Elisabeth G.E. de Vries 24.1k 2.4× 14.3k 1.6× 7.4k 1.7× 6.4k 2.1× 663 0.2× 1.0k 47.8k
William D. Figg 10.0k 1.0× 11.5k 1.3× 4.4k 1.0× 3.4k 1.1× 1.3k 0.5× 604 25.3k
Michael Gnant 13.1k 1.3× 7.8k 0.8× 5.6k 1.3× 10.0k 3.2× 361 0.1× 555 37.9k
Richard Pazdur 19.8k 1.9× 10.6k 1.2× 10.3k 2.4× 5.2k 1.7× 448 0.2× 596 37.7k
Carol DeSantis 13.0k 1.3× 7.8k 0.9× 5.1k 1.2× 6.4k 2.1× 240 0.1× 55 28.2k

Countries citing papers authored by Mark J. Ratain

Since Specialization
Citations

This map shows the geographic impact of Mark J. Ratain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Ratain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Ratain more than expected).

Fields of papers citing papers by Mark J. Ratain

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Ratain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Ratain. The network helps show where Mark J. Ratain may publish in the future.

Co-authorship network of co-authors of Mark J. Ratain

This figure shows the co-authorship network connecting the top 25 collaborators of Mark J. Ratain. A scholar is included among the top collaborators of Mark J. Ratain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark J. Ratain. Mark J. Ratain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
O’Leary, Kevin J., Edith A. Nutescu, Tai C. Chen, et al.. (2025). Results of the ACCOuNT Trial: A Multi‐Institutional Prospective Pharmacogenomics Implementation Trial for African American Inpatients. Clinical Pharmacology & Therapeutics. 119(1). 109–119. 1 indexed citations
2.
3.
Reizine, Natalie, Keith Danahey, Ping Liu, et al.. (2021). Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients. The Oncologist. 26(11). e2042–e2052. 12 indexed citations
4.
Innocenti, Federico, Alexander B. Sibley, Amy S. Etheridge, et al.. (2020). Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). Clinical Cancer Research. 27(1). 267–275. 13 indexed citations
5.
Etheridge, Amy S., Eleftheria Tsakalozou, Jacqueline Ramı́rez, et al.. (2020). Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients. The AAPS Journal. 22(3). 59–59. 4 indexed citations
6.
O’Donnell, Peter H., Theodore Karrison, Linda Janisch, et al.. (2015). Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clinical Cancer Research. 21(22). 5092–5099. 4 indexed citations
7.
Salgia, Ravi, Premal H. Patel, John Bothos, et al.. (2014). Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 20(6). 1666–1675. 56 indexed citations
8.
Wassenaar, Catherine A., David V. Conti, Soma Das, et al.. (2014). UGT1A and UGT2B Genetic Variation Alters Nicotine and Nitrosamine Glucuronidation in European and African American Smokers. Cancer Epidemiology Biomarkers & Prevention. 24(1). 94–104. 25 indexed citations
9.
Wu, Kehua, Larry House, Jacqueline Ramı́rez, Michael J. Seminerio, & Mark J. Ratain. (2013). Evaluation of Utility of Pharmacokinetic Studies in Phase I Trials of Two Oncology Drugs. Clinical Cancer Research. 19(21). 6039–6043. 5 indexed citations
10.
Wang, Jiping, Luis G. Carvajal‐Carmona, J Chu, et al.. (2013). Germline Variants and Advanced Colorectal Adenomas: Adenoma Prevention with Celecoxib Trial Genome-wide Association Study. Clinical Cancer Research. 19(23). 6430–6437. 8 indexed citations
11.
Cohen, Ezra E.W., Kehua Wu, Christine Hartford, et al.. (2012). Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients. Clinical Cancer Research. 18(17). 4785–4793. 51 indexed citations
12.
Baldwin, R. Michael, Kouros Owzar, Hitoshi Zembutsu, et al.. (2012). A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101. Clinical Cancer Research. 18(18). 5099–5109. 160 indexed citations
13.
Wheeler, Heather E., Eric R. Gamazon, Claudia Wing, et al.. (2012). Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy. Clinical Cancer Research. 19(2). 491–499. 49 indexed citations
14.
Sharma, Manish, Theodore Karrison, Yuyan Jin, et al.. (2012). Resampling Phase III Data to Assess Phase II Trial Designs and Endpoints. Clinical Cancer Research. 18(8). 2309–2315. 23 indexed citations
15.
Liu, Wanqing, Lijun He, Jacqueline Ramı́rez, et al.. (2011). Functional EGFR Germline Polymorphisms May Confer Risk for EGFR Somatic Mutations in Non–Small Cell Lung Cancer, with a Predominant Effect on Exon 19 Microdeletions. Cancer Research. 71(7). 2423–2427. 36 indexed citations
16.
Liu, Wanqing, Lijun He, Jacqueline Ramı́rez, & Mark J. Ratain. (2009). Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer Cells. Clinical Cancer Research. 15(24). 7602–7607. 15 indexed citations
17.
Maitland, Michael L., Kristen Kasza, Theodore Karrison, et al.. (2009). Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment. Clinical Cancer Research. 15(19). 6250–6257. 124 indexed citations
18.
Daugherty, Christopher K., Mark J. Ratain, Ezekiel J. Emanuel, Ann T. Farrell, & Richard L. Schilsky. (2008). Ethical, Scientific, and Regulatory Perspectives Regarding the Use of Placebos in Cancer Clinical Trials. Journal of Clinical Oncology. 26(8). 1371–1378. 40 indexed citations
19.
Ratain, Mark J. & Ezra E.W. Cohen. (2007). The Value Meal: How to Save $1,700 Per Month or More on Lapatinib. Journal of Clinical Oncology. 25(23). 3397–3398. 61 indexed citations
20.
Ratain, Mark J., Tim Eisen, Walter M. Stadler, et al.. (2006). Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 24(16). 2505–2512. 794 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Howard L. McLeod Breakdown of academic impact, for papers by Jan H.M. Schellens Breakdown of academic impact, for papers by Richard L. Schilsky Breakdown of academic impact, for papers by Tito Fojo Breakdown of academic impact, for papers by Henk‐Jan Guchelaar Breakdown of academic impact, for papers by Elisabeth G.E. de Vries Breakdown of academic impact, for papers by William D. Figg Breakdown of academic impact, for papers by Michael Gnant Breakdown of academic impact, for papers by Richard Pazdur Breakdown of academic impact, for papers by Carol DeSantis
Rankless by CCL
2026